Day 3 articles

BEST: Similar mortality among angioplasty with DES (everolimus) and surgery

BEST: Similar mortality among angioplasty with DES (everolimus) and surgery

This observational registry compared the results of myocardial revascularization with angioplasty performed using everolimus-eluting stents in patients with multivessel. The primary endpoint of the study was mortality from any cause. Side end points were infarction, stroke, and revascularization. Propensity score was used to compare populations. Between 34819 patients were eligible 9223 patients in each group

DANAMI3: Primary Angioplasty to culprit vessel versus multivessel guided by FFR

The aim of this study was to compare the usefulness of primary angioplasty only to culprit vessel versus complete revascularization guided by fractional flow reserve (FFR) in patients admitted pursuing an acute myocardial infarction with ST-segment elevation and have multiple injuries vessels. After a successful primary angioplasty to culprit artery, patients were randomized 1:1 to

MATRIX: The radial access reduces events, bivalirudin with mixed results

Two separate works are part of the MATRIX study investigating strategies to reduce bleeding and mortality in patients with acute coronary syndrome. The first part of the work that was simultaneously published in The Lancet found a significant reduction in major bleeding and mortality in patients undergoing coronary angiography and angioplasty using radial versus femoral

TOTAL: The thromboaspiration provides no benefit in primary angioplasty

In patients undergoing ST segment elevation myocardial infarction (STEMI) who received primary angioplasty, the strategy of manual thromboaspiration routine does not reduce the risk of cardiovascular death, recurrent infarction, or cardiogenic shock within 180 days compared with standard primary angioplasty with thromboaspiration only if necessary. This work was published simultaneously in The New England Journal

After 80: The octogenarian patients with acute coronary syndrome benefit from an aggressive strategy

This work published simultaneously in The New England Journal of Medicine showed that patients over eighty years may benefit from an aggressive and invasive treatment strategy that could be unnecessarily denied given age. The study was conducted in 16 centers in Norway and included 458 octogenarians patients admitted with acute coronary syndromes without ST-segment elevation

Top